European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells

Descrizione del progetto

La banca etica di cellule staminali europea sta espandendo in modo esponenziale la sua utilità e portata

La ricerca sulle cellule staminali ha un formidabile potenziale, ma ha storicamente sollevato questioni etiche sugli aspetti morali dell’uso di embrioni umani. Nell’ultimo decennio, una scoperta sorprendente si è evoluta tanto da cambiare il volto della ricerca sulle cellule staminali. Le cellule staminali pluripotenti indotte (iPSC, induced Pluripotent Stem Cells) sono cellule somatiche umane adulte, tipicamente cellule della pelle o del sangue, che vengono riprogrammate geneticamente in uno stato simile a quello delle cellule staminali embrionali. L’Europa ora gestisce una banca iPSC ed EBiSC2 sta lavorando al programma quadro che aumenterà la sua diversità, standardizzazione e capacità di servire la ricerca accademica e commerciale con un piano aziendale sostenibile.

Obiettivo

EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique banking and distribution infrastructure for research use in response to the increasing demand for human induced pluripotent stem cells (iPSC). Significant progress towards this aim has been made by EBiSC1; further resources, however, are required to ensure self-sustainability. Key partners of EBiSC1 who have delivered major assets of the current bank, join efforts to establish EBiSC2 as self-sustainable, central bank.
Based on a gap analysis of the EBiSC1 endeavours towards sustainability, and focussing on user demand, scientific excellence and productivity, EBiSC2 will deploy a business strategy for a sustainable, non-for-profit bank providing access to disease-relevant and quality-controlled iPSCs, along with comprehensive data and freedom to operate for academic and commercial use. To meet evolving requirements from industry and academia, the cell catalogue will be constantly enriched through on-demand generation of new iPSC lines, including gene-edited lines and isogenic controls, iPSC-derived and progenitor cells. EBiSC2 will distribute cell lines and develop a range of additional cell services (incl. screening panels of disease-relevant iPSC and control lines in ready-to-use-formats) to extend its offer, while reducing operational costs through state-of-the-art upscaling and automation enabling bulk production of standardised high-quality cells. Proof-of-concept studies performed jointly by academia and industry will demonstrate the reliability and robustness of the lines for disease modelling and screening and enrich the EBiSC2 catalogue with extensive data.
To bundle resources, EBiSC2 focuses on collaboration with iPSC programmes and aims to serve as central hub for EU-funded projects to bank their iPSC lines, and thus, enable long-term access by the research community to the results of European investments.

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Contribution nette de l'UE
€ 2 841 583,93
Indirizzo
HANSASTRASSE 27C
80686 Munchen
Germania

Mostra sulla mappa

Regione
Bayern Oberbayern München, Kreisfreie Stadt
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 3 432 708,93

Partecipanti (18)